
Check out our review article describing recent updates in LAG3 biology and therapeutics in @TrendsinPharma with @jwang133 and @Curie_Bio colleagues: authors.elsevier.com/c/1lFgx…


Check out our review article describing recent updates in LAG3 biology and therapeutics in @TrendsinPharma with @jwang133 and @Curie_Bio colleagues: authors.elsevier.com/c/1lFgx…

Proud to have our work with @CarolynBertozzi and Ron Levy on tumor-targeted cancer therapeutics featured in the @StanfordOTL annual report tinyurl.com/pawxhfhx; now being developed at TwoStep Therapeutics, led by lab alum Caitlyn Miller @CaitlynBioE

Congrats to lab alum Bob Chen and the @OmniAbTech team on winning "Best in Show" at @PEGSboston for their innovative and impactful xPloration B cell/ Ab screening platform.
🏆 Congratulations to @OmniAbTech , Inc. — winner of the Best of Show Award at #PEGSummit 2025! Their xPloration® Partner Access Program captured attendee votes by a landslide for its innovation and impact. Thanks to all who participated, and congrats again to the OmniAb team!

Excited to see our lab's B cell screening technology, spearheaded by Cochran alum and xCella Biosciences co-founder Bob Chen, rolled out as a now commercial instrument from antibody discovery company @OmniAbTech.
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit investors.omniab.com/investo…

Congratulations to Professor Jennifer Cochran @CochranLab who was recently elected to the National Academy of Engineering @theNAEng for protein discovery and development, biotechnology entrepreneurship, and leadership in academic bioengineering! news.stanford.edu/stories/20…

I'm excited to share our work "Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function" that's now out in PNAS! 1/3 Link to paper: pnas.org/doi/10.1073/pnas.23… Link to press release: news.stanford.edu/2024/03/11…

#JI_TopRead from @CaitlynBioE @CochranLab @CarolynBertozzi @StanfordHealth | #TLR9 agonist, PIP-CpG, enhances the CD8 #Tcell response to spontaneous tumors | #ReadTheJI #immunology #AuthorChoice #FreetoRead #TumorImmunology 👉 ow.ly/FTbV50P6FNv

In the physiologically relevant MMTV-PyMT GEMM model, @CaitlynBioE @BarfiIdit @CarolynBertozzi demonstrated that systemic delivery of a tumor integrin-targeted TLR9 agonist (PIP-CpG) led to sustained elimination [...] bit.ly/3Cu9QTC

Thrilled to announce that our new PIP-CpG paper is now live @J_Immunol . PIP-CpG is a tumor-targeting immunotherapy that is in preclinical development & we are hoping to advance it to the clinic in the coming years. doi.org/10.4049/jimmunol.220… . A 🧵👇(1/13)

Congrats to joint @StanfordBioE PhD student @hollander_mj, @CarolynBertozzi and team for this exciting collaborative work!
This tweet is unavailable

Wonderful insights and leadership from @Stanford @StanfordMed @CochranLab @KarlDeisseroth @drcwestphal #Longwoodhealthcareleaders

Congratulations to faculty fellows @alaurenoconnell, @CyertMartha & Jennifer Cochran @CochranLab for winning the 2022 @StanfordMedOFDD Faculty Women’s Forum Awards! Learn more: stanford.io/3zt8wQz

Immensely enjoyed the reviewing experience and spending the day-and-a-half on @Stanford campus with this special group of people @kumarlabucb @Widya__Mulya @chubaoyolu @TejalADesai and Darelene Soloman of @Agilent. Thank you @StanfordBioE @CochranLab for the hospitality!
Honored to serve on the External Review Committee for @StanfordBioE last week! Inspiring dept, brilliantly led by @CochranLab. Plus the views are pretty nice... Joined by @Widya__Mulya, @chubaoyolu, and @raviradhak, along w @TejalADesai and Darlene Solomon (not shown). 🌲

Join #PEGS22 Plenary Keynote Jennifer Cochran, PhD, today at 4:10pm to discuss challenges and opportunities in developing non-antibody protein therapeutics. pegsummit.com/plenary-keynot…

TLR9 (CpG) agonist was chemically conjugated to polyspecific integrin-binding peptide (PIP) that is capable to localise various types of solid tumours as explained by Caitlyn Miller from @CochranLab at @Stanford #PEGS22 @PEGSboston

Excited to share this collaborative work published in Cell on an exquisite drug-regulated CAR platform. Led by Louai Labanieh, jointly advised Bioengineering PhD student in the lab of @cm35c
Thrilled to announce that our SNIP paper is live @CellCellPress! SNIP is a high-performance drug-regulated CAR platform that is optimized for the clinic--plans for a trial are already underway @StanfordMed. #CART #Immunotherapy #SynBio #Cancer. sciencedirect.com/science/ar… 1/